<DOC>
	<DOCNO>NCT00251797</DOCNO>
	<brief_summary>The study try answer question : 1 . What high dose thalidomide brain cancer patient receive safely combination irinotecan ? 2 . How well combination work shrink brain tumor , long response treatment last ? 3 . What side effect combination drug cause ? 4 . How treatment affect patient ' quality life ( feel activity able ) ?</brief_summary>
	<brief_title>A Phase I Trial Using Combination Irinotecan Thalidomide Recurrent CNS Tumors</brief_title>
	<detailed_description>This Phase I study , mean trial generally comparatively small use determine toxicity maximum dose . Currently , `` standard '' treatment Recurrent CNS Tumors . In study , approximately 14 patient Recurrent CNS Tumors receive treatment irinotecan , intravenous drug , thalidomide , drug take mouth . Both approve Federal Food Drug Administration treatment cancer , test together brain cancer . The study try answer question : 1 . What high dose thalidomide brain cancer patient receive safely combination irinotecan ? 2 . How well combination work shrink brain tumor , long response treatment last ? 3 . What side effect combination drug cause ? 4 . How treatment affect patient ' quality life ( feel activity able ) ?</detailed_description>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Biopsy proven high grade astrocytomas , glioblastoma multiforme , anaplastic astrocytoma , anaplastic oligodendroglioma , mixed oligodendroglioma . Subjects allow definitive surgery and/or radiation treatment tumor . Subjects allow previous chemotherapy tumor . Subjects previous diagnose low grade lesion need second biopsy show transformation high grade histology . Subjects need radiographic biopsy proven recurrent disease . ECORT performance status 2 low . See appendix I. Baseline laboratory value within 30 day study entry : hemoglobin 10 gm/dl ; absolute neutrophil count 1,500 cells/ml ; platelet count 100,000 cells/ml ; SGOT/AST , SGPT/ALT , alkaline phosphatase , LDH 3high normal limit ; total bilirubin 2.0 mg/dl . Ability provide write informed consent . Age &gt; 18 year . Female patient childbearing potential must document negative serum pregnancy test within 14 day study entry . All subject must agree use effective method contraception duration treatment engage sexual activity conception possible , specified STEP program thalidomide . Therapy investigational drug ( drug available treatment IND use FDAsanctioned indication ) and/or chemotherapy regimen within 28 day study entry . Prior therapy either irinotecan thalidomide . Oxygen saturation 90 % room air . Cardiac insufficiency New York Heart Association status 2 great . Other active malignancy except basal squamous cell carcinoma skin situ cervical breast lesion . History neuropsychiatric disorder alter mental status prevent inform consent compliance protocol requirement . Known hypersensitivity allergic reaction study drug . Women stage pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Brain cancer</keyword>
	<keyword>Recurrent CNS tumor</keyword>
</DOC>